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Abstract
In our chapter, we overview the main clinical conditions that increase arrhythmogenic‐
ity, and we present the surface electrocardiogram (ECG) markers that could be suitable
for the prediction of atrial and ventricular arrhythmias. We highlight the clinical value
of the prolongation of the P‐wave duration and P dispersion (Pd) in the prediction of
atrial fibrillation, and we also expound the utility of QT interval, T‐wave peak‐to‐end
interval  (Tpe),  and  Tpe/QT  ratio  (known  as  arrhythmogenic  index  (AIX))  in  the
prediction of ventricular arrhythmias. Furthermore, we present the results of our clinical
investigations with regard to surface ECG markers among patients with increased
arrhythmia vulnerability. Moreover, we mention other, novel, effectively used ECG
markers.
Keywords: atrial fibrillation, P dispersion, P‐wave interval, QT interval, T‐wave peak‐
to‐end interval, ECG markers, ventricular arrhythmias
1. Introduction
There are several diseases which may affect the pulse generation and the conduction in the
heart.  Patients suffering from these clinical  conditions have increased probability for the
occurrence of atrial and ventricular arrhythmias [1–4]. Numerous studies have been dealing
with  certain  surface  electrocardiogram  (ECG)  markers  which  could  be  suitable  for  the
prevention of various cardiac rhythm disturbances [5–7]. Previously, it has been shown that
the prolongation of the P‐wave duration and P dispersion (Pd) can predict atrial arrhythmias
[5, 8, 9]. Moreover, it has also been demonstrated that the prolongation of QT interval, T‐wave
peak‐to‐end interval (Tpe) and Tpe/QT ratio (known as arrhythmogenic index—AIX) could
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predict ventricular arrhythmias [6, 7]. In our chapter we would like to present the electrophy‐
siological  substrates  and  pathogenetic  factors  taking  part  in  arrhythmogenesis  and  to
demonstrate ECG‐based diagnostic opportunities that can help in the prediction and preven‐
tion of arrhythmias. Furthermore, we present the results of our studies to demonstrate the
clinical use of these ECG markers.
2. Non-invasive electrocardiographic markers in the prediction of atrial
fibrillation
2.1. Epidemiology and electrophysiological background of atrial fibrillation
The most common form of rhythm disturbances is atrial fibrillation (AF). Its prevalence is
0.12–0.16% among people younger than 49 years, 3.7–4.2% with regard to people aged 60–70
years and 10–17% among people aged 80 years or older [10]. Age, gender, hypertension, dia‐
betes mellitus, heart failure and valvular heart disease are independent risk factors that may
play a role in arrhythmogenesis. Moreover, AF may be caused by hyperthyroidism and ex‐
cessive alcohol consumption [11, 12] (Table 1).
Cardiovascular causes of atrial fibrillation (%)
Ischemic heart disease 17
Hypertensive cardiomyopathy 21
Valvulopathies 15
Dilated cardiomyopathy 9
Hypertrophic cardiomyopathy 5
Other structural heart diseases 9
Non‐structural heart diseases 29
Table 1. Cardiovascular causes of atrial fibrillation.
In patients with end‐stage renal failure, its prevalence is approximately 13%. Interestingly, 10%
of subjects suffering from ‘lone’ AF have no comorbidity, detectable underlying structural or
functional heart disease. Previous studies have also demonstrated that nearly 30% of patients
with atrial fibrillation may have a positive family history. The predisposition for arrhythmia
events was shown to be inherited in an autosomal dominant pattern. In a small proportion of
familial AF, specific mutant genes were identified, and mutations were detected mainly in
KCNE2, KCNJ2, and KCNQ1. While encoding the protein products of certain potassium
channels, these are suggested to play a role in the maintenance of sinus rhythm [13–16].
Atrial anisotropy is thought to be one of the key points of increased atrial arrhythmia vulner‐
ability, where the inhomogeneous spreading of atrial impulses can be secondary to an altered
histological structure of the atrial myocardium (hypertrophy, fibrosis, and fatty degeneration)
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[17–19]. Consequently, the dilation of both atria may appear representing an increased
susceptibility for atrial arrhythmias [20]. Furthermore, increase in cardiac preload and
afterload and electrolyte imbalances may also have an additive role in the increase of atrial
arrhythmogenicity and reentry mechanism, where the latter is the electrophysiological
substrate for atrial fibrillation.
2.2. Clinical consequences of atrial fibrillation
Irregular and high ventricular response due to AF, atrioventricular dissociation and the lack
of atrial systole may contribute to low cardiac output syndrome. Patients usually complain
about palpitation, fatigue, dyspnea, vertigo/dizziness, and chest pain. However, 11% of these
patients are asymptomatic. Decrease in atrial blood flow velocity gives the chance for atrial
thrombus formation. Mortality caused by atrial fibrillation is primarily connected with an
increased risk for thromboembolic events and stroke (Figure 1) [10, 11, 21].
Figure 1. Pathomechanism and consequences of atrial fibrillation.
2.3. Electrocardiographic prediction of AF
2.3.1. P-wave duration and P dispersion
Due to the structural and electrophysiological heterogeneity of the left atrium, unidirectional
block can occur, which plays a role in the genesis of atrial microreentry and premature beats.
In patients with paroxysmal atrial fibrillation during sinus rhythm, the intra‐ and interatrial
conduction time of the sinus impulse were shown to lengthen, and the duration of the P wave
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measured on a surface electrocardiogram (ECG) is increased, where the prolongation of atrial
conduction time is proportional with the duration of P‐wave interval. Previously, it has also
been shown that the prolongation of P‐wave duration and P dispersion (Pd) can predict atrial
arrhythmias. P‐wave duration of the surface electrocardiogram is specified as the section from
the first electrical activity following the T wave (or the U wave) to the intersection of the P
wave’s descending branch and the isoelectric line. The investigator should analyze three
consecutive P waves each lead and calculate their average duration, where the result is the P
wave duration in the given lead (Figure 2). P dispersion (Pd) is determined as the difference
between the longest and shortest P interval. P interval and Pd can be corrected to the heart rate
(Pmaxc, Pdc) according to Bazett’s formula (Pmaxc = Pmax/√RR (ms), Pdc = Pd/√RR (ms))
(Figure 2) [5, 8, 9].
Figure 2. Measurement of P‐wave duration on the surface ECG.
2.3.2. Alterations of P-wave duration and P dispersion among patients participating renal
replacement therapy
The incidence of atrial fibrillation is increased during hemodialysis (HD), and the prolongation
of P‐wave duration has been shown to be a valuable indicator of atrial conduction disturbances.
Based on the aforementioned, we analyzed the length of P‐wave interval and P dispersion on
the surface ECG of 28 patients with end‐stage renal failure on extracorporeal renal replacement
therapies. According to our results, P‐wave duration and P dispersion increased significantly
at the end of the hemodialysis sessions compared to those measured at the beginning, and they
remained lengthened 2 hours after the treatment [22]. Previously, a novel convective‐transport‐
based renal replacement method, the hemodiafiltration (HDF), has been introduced. Lately,
convective treatment has been proven to reduce mortality of these particular patients with end‐
stage kidney disease. This favorable effect of HDF may be partly caused by the decreased
occurrence of atrial and ventricular arrhythmias. We intended to examine whether these
suggested differences between hemodialysis and hemodiafiltration with regard to arrhythmia
vulnerability could be shown as alterations of P interval and P dispersion on the surface ECG.
We obtained clinical data from 30 patients receiving HDF over a period of 3 months; and the
same group of patients was then evaluated during treatment with conventional HD for at least
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another 3 months. The duration of the P wave and Pd increased significantly during HD, but
no such significant prolongations were observed in the case of HDF (Figure 3) [23].
Figure 3. Changes in corrected P‐wave duration (P interval) and corrected P dispersion (Pd) during hemodialysis and
hemodiafiltration.
2.3.3. Biphasic P wave
Slow and inhomogeneous atrial conduction, thus atrial anisotropy, can appear as biphasic P
wave in the inferior electrocardiographic leads (leads II, III, and aVF). In nearly 75% of patients
with paroxysmal, AF has an increased duration of the initial portion of P wave in lead III [24].
Various investigations have reported the clinical value of P‐wave measurements in the
prediction of AF (Table 2) [22, 23, 25–30].
Underlying clinical condition References
Hyperthyroidism [25, 26]
Postcardiac surgery [27, 28]
Renal failure and renal replacement therapy [22, 23]
Pulmonary diseases [29, 30]
Table 2. Studies which investigated alterations of the atrial phase of surface ECG.
2.3.4. Investigation of Ta wave
Inhomogeneous atrial repolarization may also play an additive role in the genesis of atrial
arrhythmias and paroxysmal atrial fibrillation. Therefore, ECG analysis of atrial repolarization
may provide further data on atrial arrhythmia vulnerability. Recently, a novel electrocardio‐
graphic marker the atrial T wave, also known Ta wave, has been shown to characterize atrial
repolarization in patients with sinus rhythm. Due to its small amplitude within the PQ
segment, signal averaging is necessary to soften the measurements. Moreover, in patients with
physiologic atrioventricular conduction, it is generally localized in the subsequent QRS
complex (name for the combination of three of the graphical deflections seen on a surface ECG
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which corresponds to the ventricular depolarization) holding the measurements to be impos‐
sible. Nevertheless, characteristics of the detectable atrial repolarization phase of the ECG have
been compared between individuals with sinus rhythm and paroxysmal AF. However, no
significant differences with regard to the morphology, amplitude and length of Ta wave have
been clearly elucidated yet [31].
3. Ventricular arrhythmias and sudden cardiac death
3.1. The role of electrocardiographic markers in the prevention of ventricular rhythm
disturbances and sudden cardiac death
Despite the improvement in statistical data, cardiovascular diseases are responsible for
approximately 17 million deaths every year in the world, where approximately 25% is related
to sudden cardiac death [32]. Malignant ventricular arrhythmias (e.g. ventricular tachycardia
and ventricular fibrillation) are the most important underlying rhythm disturbances respon‐
sible for these unfavorable statistics. The incidence of these ventricular arrhythmias correlates
with age primarily due to the higher prevalence of coronary artery disease [33]. Sudden cardiac
death has an estimated incidence of 1100–9000 in Europe and 800–6200 in the United States
every year [32].
3.2. Pathomechanism of ventricular arrhythmias and sudden cardiac death
Various factors have been shown to play a role in the genesis of ventricular arrhythmias. Both
congenital factors and acquired pathophysiological mechanisms can provoke these cardiac
rhythm disturbances [33]. Previously, it has been demonstrated that genetic predisposition can
contribute to the genesis of sudden cardiac death. Fifty percent increase has been confirmed
in the likelihood of the occurrence of malignant ventricular arrhythmias in the presence of a
family history of sudden cardiac death [34]. Furthermore, it has been shown that familial
sudden death appears more frequently in patients resuscitated from primary ventricular
fibrillation [35]. Previously, single nucleotide polymorphisms located in the 21q21 and 2q24.2
loci have been also shown to increase the risk of sudden cardiac death [36, 37]. However, certain
concerns were raised with regard to these results, and further investigations are needed. The
risk of sudden cardiac death is higher in males [38, 39]. On the other hand, coronary artery
disease, ischemic cardiomyopathy and heart failure, hypertensive heart disease, and lipid
abnormalities are the most important acquired provoking factors with regard to ventricular
arrhythmogenesis and sudden cardiac death [3, 38]. Interestingly, kidney disease and hemo‐
dialysis itself have been demonstrated to be significant underlying substrates for the genesis
of ventricular arrhythmias. The incidence of sudden cardiac death in patients suffering from
kidney diseases was shown to be approximately 1.4–25% [4]. Furthermore, physical inactivity,
smoking, alcohol abuse, and inadequate alimentation are significant pathophysiologic factors
that may contribute to ventricular arrhythmogenesis [39] (Table 3). Most importantly 50% of
sudden death appears in patients without a previously known heart disease, but most of these
individuals suffer from ischemic heart disease. Therefore, 40% of the reduction in sudden
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arrhythmia death is due to the effective management and prevention of coronary artery disease
[38, 39]. Left ventricular systolic dysfunction has also been proven to be an important under‐
lying factor for ventricular arrhythmogenesis. Left ventricular ejection fraction, an echocar‐
diographic parameter, has been shown in association with increased probability for sudden
cardiac death mainly in patients with myocardial infarction. Related to heart failure, certain
biochemical indicators such as the B‐type natriuretic peptide and N‐terminal pro‐B‐type
natriuretic peptide have also been shown to be useful in the risk stratification of sudden cardiac
death [40, 41].
Congenital or acquired causes Temporary factors
• Coronary artery disease • Electrolyte imbalance
◦ Hypokalemia, hypomagnesemia
• Hypertensive heart disease • Endocrinological disorders
◦ Thyroid
◦ Suprarenal gland
• Cardiomyopathies
◦ Hypertrophic
◦ Dilated
◦ Right ventricular dysplasia
• Myocarditis
• Pericarditis
• Valvular diseases • Toxic effects
◦ Alcohol
◦ Certain antibiotics
◦ Antifungal agents
◦ Antidepressants
• Primary electrophysiologic causes (channelopathies)
◦ Brugada syndrome
◦ Long QT syndrome
◦ Short QT syndrome
• PH abnormalities
• Smoking
• Congenital heart diseases • Postoperative period
• Comorbid factors
◦ Pulmonary diseases
◦ Kidney disease
• Malnutrition
• Abdominal distension
Table 3. Common causes of ventricular arrhythmias are shown. Congenital and acquired diseases may play a role in
ventricular arrhythmogenesis; furthermore, temporary factors can additionally increase the susceptibility for rhythm
disturbances.
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Figure 4. The monophasic action potential of a ventricular myocardial cell is shown. The plateau phase largely de‐
pends on the potassium and the calcium ion channel activity. The longer the plateau phase, the more increased the
myocardial cell’s repolarization. M cells show a prominent prolongation in action potential diameter and develop early
after depolarizations in response to rapidly activating delayed rectifier potassium current (IKr) blockers.
3.3. Ventricular repolarization and cardiac arrhythmias
Secondary to the pathophysiologic factors, the electrophysiological properties of the myocar‐
dial cells can change, resulting in the modification of the duration and amplitude of the
monophasic action potential featuring the myocardial cell’s electrical properties (Figure 4) [42].
As a result, inhomogeneous ventricular repolarization and anisotropy may appear, which
seem to be one of the electrophysiological key points in the genesis of ventricular arrhythmias.
Previously, it has been shown that a mid‐myocardial population of cardiac myocytes (e.g. M
cells) can play an important role in the prolongation of repolarizational dispersion [43, 44].
From an electrophysiologic point of view, these special cells have been shown to be between
Purkinje and ventricular myocytes, while they show a significant prolongation in action
potential diameter and develop early after depolarizations in response to rapidly activating
delayed rectifier potassium current (IKr) blockers [45]. In the meantime epicardial and
endocardial myocytes are less likely to do so. Accordingly, due to certain drug therapies (e.g.
amiodarone and sotalol) or other provoking factors, an exaggerated dispersion in transmural
action potential duration may come alive, resulting in an increased danger of transmural
inhomogeneity of ventricular repolarization and an increased susceptibility for ventricular
arrhythmias (Figure 4) [42, 46].
3.4. QT interval and dispersion
QT interval represents the electrical repolarization of the ventricular myocardium. Patients
with increased susceptibility for the development of malignant ventricular dysrhythmias can
be identified with the determination of QT interval [47]. Duration of the QT interval is changing
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in the different leads of the surface electrocardiogram. QT dispersion (QTd) is derived from
the interlead alterations of QT intervals. This is a useful parameter to describe the differences
in ventricular recovery times representing the prolongation of myocardial repolarization [48].
QT dispersion has also been proven to correlate with the duration of the monophasic action
potential of the epicardial myocardial cells. Since these electrocardiographic markers have
been introduced to predict ventricular arrhythmias and sudden cardiac death, they are
considered to be among one of the non‐invasive parameters [49]. The prolongation of QT
interval can be congenital (e.g. Romano‐Ward or Jervell and Lange‐Nielsen syndromes) or
acquired. Congenital syndromes are caused by mutations in at least five different ion channel
genes resulting in the defects in the sodium channel (SCN5A, LQT3), the rapidly activating
delayed rectifier channel (IKr) (HERG, LQT2 or KCNE2, LQT6), and the slowly activating
delayed rectifier channel (IKs) (KvLQT1, LQT1 or KCNE1, LQT5), respectively [50]. QT
prolongation can be acquired and may occur after acute myocardial infarction, congestive
heath failure, dyslipidemia, diabetes mellitus, sudden sympathetic autonomic activation
(triggered activity) and renal failure [6, 51–55]. In individuals with liver cirrhosis, the length‐
ening of QT interval has not been shown to be related to the etiology of the liver disease and
seems to appear both in alcoholic and nonalcoholic patients [46]. In addition, QT prolongation
may be associated to certain drug interactions (e.g. haloperidol, methadone, amiodarone,
sotalol, selective serotonin reuptake inhibitors, macrolide antibiotics, and antifungal agents)
[56]. QT dispersion may also be affected by various diseases (amyloidosis, sarcoidosis,
carcinoid, hemochromatosis, diabetes mellitus, thyroid dysfunction, or Parkinson’s disease)
[57–63].
3.5. QT measurements and their clinical use
Since these repolarizational variables are modified by numerous causes, the thorough inves‐
tigation of patient’s history is one of the leading points during the determination of arrhythmia
risk. Considering the required standards for precision, the measurement of QT interval still
remains subjective as the terminal point of the T wave usually cannot be clearly defined. QT
interval can be measured manually or automatically [49, 64]. During manual investigations,
improvement in consistency of the results and the minimization of interobserver variability
may be achieved by the measurements performed by one examiner. During the threshold
method, the point where the T wave reaches the isoelectric line is determined as its end.
According to the tangent method, the end of T wave is defined as the point where a given
tangent line overtakes the isoelectric line, where the tangent line is the last part of the T wave
at its maximum downslope. To get more accurate data, the average of three sequential periods
in a given lead is calculated and defined as QT interval [47, 48] (Figure 5). QT measurements
may also be performed by means of computers with the superimposed median beat method,
where an electrocardiographic complex is constructed for each of the 12 leads. These medians
are superimposed on each other. Afterwards, QT interval is determined from the earliest onset
of the Q wave to the latest offset of the T wave. Moreover, QT interval can be measured from
the point of maximum convergence for the Q‐wave onset to the T‐wave offset [48].
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Figure 5. The manual measurement of the QT interval of the 12‐lead surface electrocardiogram. The calculation and
averaging of three consecutive sections may provide a more accurate result in the given lead.
Ventricular rate has a significant influence on QT interval’s duration. When heart rate acceler‐
ates, QT interval shortens. Therefore, QT interval has to be corrected to heart rate (QTc) using
the Bazett's formula (QTc = QT/√RR) (borderline QTc, male 431–450 ms and female 451–470 ms;
abnormal QTc, male ≥ 451 ms and female ≥471 ms). Normal values of QT dispersion vary in a
very wide range from 10 to 71 ms. The QTc >450 ms value has been reported to have an
increased risk for ventricular arrhythmias [49]. With regard to patients suffering from liver
cirrhosis, a special relationship between QT interval duration and heart rate exists; thus, a
specific ‘cirrhosis formula’—similar to the Fridericia’s—should be used. Measurement of QT
interval and dispersion can help in the monitoring of antiarrhythmic therapy especially with
the widely used antiarrhythmic drugs, amiodarone and sotalol [46, 56]. Previously, the
prolongation of the QT dispersion has been shown to represent recurrent ischemia after
percutaneous transluminal coronary angioplasty. Lately, the eligibility of QT dispersion in the
evaluation of long‐term outcome of patients waiting for cardiac transplantation has also been
discussed. Life‐threatening ventricular rhythm disturbances of patients with long QT syn‐
dromes often caused by a sudden increase in sympathetic activity, and beta‐blockers have been
shown to significantly reduce these arrhythmic episodes. In patients who remain symptomatic
despite treatment with beta‐blockers (mostly patients with LQT2 and LQT3), left cardiac
sympathetic denervation may be a therapeutic solution. In the case of cardiac arrest, ICD
should be implanted; however, there are controversial data regarding the ICD therapy in
subjects with no such previous history [47, 49, 50].
3.5.1. Changes in QT interval and QT dispersion in hyperlipidemia and kidney disease
The susceptibility to malignant ventricular arrhythmias increases proportionally with the
lengthening of QT interval. Progressive atherosclerosis is an independent risk factor of the
occurrence of sudden cardiac death. In our study clinical data of 96 patients with hyperlipi‐
demia were compared to 103 controls. Serum LDL‐C (low density lipoprotein – cholesterol)
and Tg levels were positively correlated with corrected QT interval and QT dispersion, so lipid
parameters may affect these ECG markers [65]. Furthermore, we investigated the ECG
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parameters representing ventricular repolarization in the case of 30 patients receiving
hemodiafiltration (HDF) over a period of 3 months, and we obtained data from the same
patients after treatment with conventional hemodialysis (HD) for at least another 3 months.
The duration of the QT interval and QT dispersion was only increased significantly in the case
of HD, but no similar significant prolongations in the case of HDF could be observed (Figure 6)
[66].
Figure 6. Prolongation of corrected QT interval and corrected QT dispersion (QTd) during different renal replacement
therapies.
3.6. QT variability
Previously, numerous studies have been dealing with the beat‐to‐beat variability in QT interval
of the surface electrocardiogram in order to quantify temporal dispersion of ventricular
repolarization [67]. Its increase has been associated to long QT syndrome, heart failure,
myocardial ischemia, hypertrophic cardiomyopathy, and panic disorder [68–72]. Increased QT
variability has also been shown to predict appropriate implantable cardioverter‐defibrillator
shocks. Moreover, increased variability has been observed with regard to sudden cardiac death
in patients with myocardial infarction without ICD therapy [73, 74]. QT variability may also
increase in healthy people with postural change from the supine to standing position and after
activities that increase beta‐adrenergic tone [75]. QT variability is measured by a special
computer algorithm that is able to analyze QT‐interval signals that are derived from multiple
channels [76].
3.7. Short QT syndrome
Short QT syndrome, an inherited disease, is characterized by QT interval <300 ms and an
increased risk for paroxysmal atrial fibrillation and ventricular arrhythmias. Short QT
syndrome is also related to an increased risk of sudden cardiac death, likely caused by
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ventricular fibrillation [77]. More genetic mutations of sodium and calcium channels have been
reported to be an underlying substrate for this clinical entity (KCNH2, KCNQ1 and KCNJ2).
Increased activity of outward potassium currents in phase 2 and phase 3 leads to the decreased
duration of cardiac action potential, resulting in the shortening of refractory periods. This
mechanism is thought to be responsible for the genesis of reentry mechanism and increased
dispersion of ventricular repolarization [77, 78]. Besides ICD, antiarrhythmic drug therapy also
has to be taken into consideration. Only quinidine, a sodium channel blocker, has been shown
to normalize the QT interval at resting heart rates, while it restored the heart rate dependence
of QT interval towards an adaptation range of healthy individuals by prolonging the duration
of cardiac action potential [79, 80]. However its further effects remain to be elucidated.
3.8. Early repolarization
Recently, a J‐point elevation of ≥0.1 mV in two adjacent leads occurring on the surface electro‐
cardiogram manifested as terminal QRS slurring (the transition from the QRS segment to the
ST segment) or notching (a positive deflection inscribed on terminal QRS complex) associated
with concave upward ST‐segment elevation and prominent T waves has been introduced as
an early‐repolarization (ER) pattern [81, 82]. A transmural voltage gradient between the
ventricular epicardium and endocardium may be responsible for this phenomenon [83, 84].
ER commonly occurs in the general population (approximately 10%) and often exists in athletes
and youngsters and at slower heart rates in individuals without known cardiac diseases [85].
However, recently, studies have emphasized a possible link between ER and life‐threatening
ventricular dysrhythmias [86]. The electrocardiographic signs of ER may be associated with a
shorter QT interval and can display high dynamicity affected by ventricular rate and pauses,
mediators of autonomic nervous system, androgen hormones and certain drugs (sodium
channel blockers, beta‐blockers, quinidine and isoproterenol) [87–91]. Importantly, a distinc‐
tion between ER, short QT and Brugada syndromes sometimes proves to be difficult on the
basis of electrocardiography, where genetic tests may be valuable in identifying the underlying
ion channel defect [89, 92, 93]. Subjects with ECG signs of classic ER have minimal risk for
ventricular arrhythmias, and the recognition of high‐risk patients is often a real challenge [93,
94]. The susceptibility for ventricular arrhythmias may increase when ER is associated with
heart failure, hypokalemia or acute coronary syndrome [95, 96]. Furthermore, the family
history of ERS or sudden death, the extension of electrocardiographic signs of ER into a
Brugada syndrome pattern, the presence of horizontal ST segment following the J wave, ER
signs localized in inferior or infero‐lateral leads, the presence of coupled ventricular premature
beats, increase in parasympathetic tone, also the association of ER with short QT intervals,
young age and male gender draw the attention to a higher arrhythmia risk [94, 97–99]. In high‐
risk patients with ER syndrome and a family history of sudden death, quinidine and/or ICD
implantation can be a therapeutic solution. Furthermore, cilostazol, a phosphodiesterase III
inhibitor, has been shown to normalize the aforementioned ECG changes. In the case of ER
syndrome‐mediated electrical changes, a beta‐adrenergic agent (e.g. isoproterenol) may be a
useful therapeutic solution [100].
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3.9. T-wave alternans (TWA) and T-wave peak-to-end interval
T‐wave alternans is defined as an alteration in the morphology of the T wave in an AB‐AB or
every‐other‐beat pattern (Figure 7). It has been introduced as a non‐invasive ECG marker for
evaluating spatiotemporal heterogeneity of ventricular repolarization [101]. By reflecting the
intracellular changes in calcium handling and showing beat‐to‐beat alternations of action
potential duration of the ventricular cells, this electrocardiographic parameter seems to be
capable for the prediction of ventricular repolarizational heterogeneity and the predisposition
for ventricular arrhythmias [102].
Figure 7. Alternation in the morphology of T waves on the surface electrocardiogram. Based on Narayan [101].
The electronic filtering of the T wave on a ‘microvolt level’ (i.e. microvolt T‐wave alternans
(MTWA)) creates even greater applicability of this non‐invasive electrocardiographic method
[103]. Therefore, MTWA has also been introduced as a valuable tool for the risk stratification
of sudden cardiac death. Importantly, MTWA seems to have a particular role in the risk
stratification between patients who need implantable cardiac defibrillators and those who do
not [103–105]. TWA test is usually conducted during treadmill or bicycle exercise or with the
administration of chronotropic agents in order to achieve an optimal ventricular rate, since
TWA may occur in normal individuals at heart rates >120 beats/min. Occasionally, pacemaker
stimulation required to maintain stable ventricular frequency. A target ventricular rate range
of 105–110/min was determined for pathologic alternans in adults. If ectopic or premature beats
constitute >10% of beats, the affected portion of the electrocardiogram is not recommended for
TWA examination [106–108]. MTWA tests’ results can be positive, negative or indeterminate.
Patients with indeterminate results have to be investigated again [109]. In the case of a negative
test, the probability of malignant ventricular arrhythmias and sudden cardiac death are low
(with 98% accuracy for follow‐up periods of 12–24 months in clinical studies) [110]. However,
these patients have to undergo a repeated investigation every 12–24 months. Subjects with a
negative MTWA test are not likely to require a defibrillator. Importantly, TWA testing may be
equivalent to an electrophysiology study. Nevertheless, at present there is no definitive
evidence available that can prove the real effectiveness of this method in guiding the antiar‐
rhythmic treatment [107]. Previously a novel electrocardiographic marker, T‐wave peak‐to‐
end interval (Tpe) has been reported to represent the transmural dispersion of repolarization
of the left ventricle and the vulnerability to ventricular arrhythmias [6, 111]. The prolongation
of Tpe has been shown to be associated with increased mortality rates in long QT syndrome,
acute myocardial infarction, sleep apnea and hypertrophic cardiomyopathy [6, 111, 112].
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Reference value of T‐wave peak‐to‐end interval is considered to be 94 ms in the case of male
and 92 ms with regard to female subjects [113]. In addition, the Tpe/QT ratio is used as an
arrhythmogenic index (AIX) of ventricular arrhythmogenesis [7, 114]. It has been demonstrat‐
ed that in patients with acquired QT syndrome, the Tpe/QT ratio is superior to QT interval
and QT dispersion in the prediction of torsades de pointes ventricular tachycardia [115]. Also,
Tpe/QT ratio was shown to be a valuable predictor of sudden cardiac death [116–118].
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